The mRNA flu vaccine study will enroll roughly 25,000 healthy U.S. adults.
Pfizer is not the only company to develop an mRNA flu vaccine. In December, Moderna (Nasdaq:MRNA) announced positive interim data from a Phase 1 study of its quadrivalent seasonal flu vaccine candidate, mRNA-1010. That data, however, disappointed investors, as mRNA-1010 had a similar performance to Sanofi’s (NSDQ:SNY) Fluzone HD flu vaccine.
Moderna’s (Nasdaq:MRNA) mRNA-1010 flu vaccine is now in a Phase 3 study. That study is fully enrolled with approximately 6,000 participants. Moderna anticipates the va…